Advertisement

Osteoporosis International

, Volume 18, Issue 10, pp 1345–1353 | Cite as

Fragility fractures and bone mineral density in HIV positive women: a case-control population-based study

  • J. Prior
  • D. Burdge
  • E. Maan
  • R. Milner
  • C. Hankins
  • M. Klein
  • S. Walmsley
Original Article

Abstract

Summary

This Canadian study of bone health showed that HIV+ women were more likely to have had fragility fractures (OR 1.7) but had BMD values that were not different than women from a national population-based cohort.

Introduction

Given that 17.5 million women globally are HIV-infected and living longer on anti-retroviral therapy (ART+), it is essential to determine whether they are at risk for osteoporosis as is currently assumed.

Methods

Assessment of osteoporosis risk factors and lifetime low-trauma (fragility) fracture history used a common interviewer-administered questionnaire and phantom-adjusted bone mineral density (BMD). This study compared HIV+ Canadian women with age- and region-matched control women (1:3) from a national population-based study of osteoporosis.

Results

One hundred and thirty-eight HIV+ women (100 ART+, 38 ART-) were compared with 402 controls. There were no differences in age (37.7 vs. 38.0 years), BMI (25.0 vs. 26.2), family history of osteoporosis, exercise history, alcohol or calcium intakes, age at menarche, oral contraceptive use or parity. HIV+ cases included more Aboriginal and Black women (12.5% and 16.2 vs. 2% and 1%, respectively), smoked and used injection drugs (53%) more, were more often treated with glucocorticoids, had oligomenorrhea, and reported 10-kg weight cycling. Significantly more HIV+ women reported lifetime fragility fractures (26.1% vs. 17.3; OR 1.7, 95% CI 1.1, 2.6). HIV+ and control women did not differ in BMD: spine 1.0 ± 0.12 vs.1.0 ± 0.14 g/cm2 (diff. 0.0, 95% CI −0.27, 0.27) or total femur 0.91 ± 0.15 vs. 0.93 ± 0.12 g/cm2 (diff 0.02, 95% CI +0.005, −0.045).

Conclusion

HIV+ women reported significantly more past osteoporotic fractures than population-based controls despite normal BMD. Research is needed to assess bone microarchitecture and develop a reliable fracture risk assessment tool for HIV+ women.

Keywords

Bone mineral density Case-population-control Fragility fractures HIV positive Premenopausal Women 

Notes

Acknowledgements

The authors thank all the women who participated. This study would not have been possible without approval from the Data Analysis and Publications Committee of the Canadian Multicentre Osteoporosis Study and the cooperation of C. Berger and the CaMOS Data Management Centre. Dr. D. Burdge and C. Morris obtained funding for this study as a grant from CANFAR. The following physician directors of individual Canadian Women’s HIV Study centres, in addition to the authors (DRB, CH, MBK and SW) contributed importantly to this study: A Rachlis; F. Smaill; S Trottier, W Wobeser, and K Williams. The bone mineral density measurements were made possible with the assistance of Dr. K. Kruse and the Osteoporosis Clinic at the Women’s Health Centre in Vancouver. Dr. Stuart Jackson provided quality assurance and converted all DXA data based on common phantom data. Dr. R. Sebaldt oversaw data entry for the CWHS data.

The Canadian Multicentre Osteoporosis Study was funded by the Senior’s Independence Research Program, through the National Health Research and Development Program of Health Canada (Project No. 6605-4003-OS), The Medical Research Council of Canada, MRC-PMAC Health Program, Merck Frosst Canada Inc., Eli Lilly Canada Inc., Procter and Gamble Pharmaceuticals Canada Inc., Novartis Pharmaceuticals Inc., Aventis Pharma Inc., The Dairy Farmers of Canada, The Arthritis Society.

References

  1. 1.
    Thomas J, Doherty SM (2003) HIV infection-a risk factor for osteoporosis. J Acquir Immune Defic Syndr 33(3):281–291PubMedGoogle Scholar
  2. 2.
    Guaraldi G, Ventura P, Albuzza M, Orlando G, Bedini A, Amorico G et al (2001) Pathological fractures in AIDS patients with osteopenia and osteoporosis induced by antiretroviral therapy. AIDS 15(1):137–138PubMedCrossRefGoogle Scholar
  3. 3.
    Dolan SE, Huang JS, Killilea KM, Sullivan MP, Aliabadi N, Grinspoon S (2004) Reduced bone density in HIV-infected women. AIDS 18(3):475–483PubMedCrossRefGoogle Scholar
  4. 4.
    Stephens EA, Das R, Madge S, Barter J, Johnson MA (1999) Symptomatic osteoporosis in two young HIV-positive African women. AIDS 13(18):2605–2606PubMedCrossRefGoogle Scholar
  5. 5.
    McComsey GA, Huang JS, Woolley IJ, Young B, Sax PE, Gerber M et al (2004) Fragility fractures in HIV-infected patients: need for better understanding of diagnosis and management. J Int Assoc Physicians AIDS Care (Chic.Ill.) 3(3):86–91CrossRefGoogle Scholar
  6. 6.
    Yin M, Dobkin J, Brudney K, Becker C, Zadel JL, Manandhar M et al (2005) Bone mass and mineral metabolism in HIV+ postmenopausal women. Osteoporos.Int published on-line March 2005Google Scholar
  7. 7.
    Madeddu G, Spanu A, Solinas P, Calia GM, Lovigu C, Chessa F et al (2004) Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy. Q J Nucl Med Mol Imaging 48(1):39–48PubMedGoogle Scholar
  8. 8.
    Martin K, Lawson-Ayayi S, Miremont-Salame G, Blaizeau MJ, Balestre E, Lacoste D et al (2004) Symptomatic bone disorders in HIV-infected patients: incidence in the Aquitaine cohort (1999–2002). HIV Med 5(6):421–426PubMedCrossRefGoogle Scholar
  9. 9.
    Bruera D, Luna N, David DO, Bergoglio LM, Zamudio J (2003) Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS 17(13):1917–1923PubMedCrossRefGoogle Scholar
  10. 10.
    Tenenhouse A, Joseph L, Kreiger N, Poliquin S, Murray TM, Prior JC et al (2000) Estimation of prevalence of low bone density in Canadian women and men using a population-specific DEXA reference standard: the Canadian Multicentre Osteoporosis Study (CaMos). Osteoporos Int 11:897–904PubMedCrossRefGoogle Scholar
  11. 11.
    Loiseau-Peres S, Delaunay C, Poupon S, Lespessailles E, Ballouche N, Arsac P et al (2002) Osteopenia in patients infected by the human immunodeficiency virus. A case control study. Joint Bone Spine 69(5):482–485PubMedCrossRefGoogle Scholar
  12. 12.
    O’Neil TW, Felsenberg D, Varlow J, Cooper C, Kanis JA, Silman AJ et al (1996) The prevalence of vertebral deformity in European men and women: the European Vertebral Osteoporosis Study. J Bone Mineral Res 11:1010–1018CrossRefGoogle Scholar
  13. 13.
    Hankins C, Lapointe N, Walmsley S (1998) Participation in clinical trials among women living with HIV in Canada. Canadian Women’s HIV Study Group. CMAJ 159(11):1359–1365PubMedGoogle Scholar
  14. 14.
    Kreiger N, Tenenhouse A, Joseph L, Mackenzie MD, Poliquin S, Brown JP et al (1999) The Canadian Multicentre Osteoporosis Study (CaMos): Background, rationale, methods. Can J Aging 18:376–387Google Scholar
  15. 15.
    Archibald, C. HIV/AIDS EPI Updates. http://www.phac-aspc.gc.ca. 1-13-2006. Ref Type: Electronic Citation
  16. 16.
    Pearson D, Cawte SA, Green DJ (2002) A comparison of phantoms for cross-calibration of lumbar spine DXA. Osteoporos Int 13(12):948–954PubMedCrossRefGoogle Scholar
  17. 17.
    Petit MA, Beck TJ, Lin HM, Bentley C, Legro RS, Lloyd T (2004) Femoral bone structural geometry adapts to mechanical loading and is influenced by sex steroids: The Penn State Young Women’s Health Study. Bone 35(3):750–759PubMedCrossRefGoogle Scholar
  18. 18.
    Luckey MM, Wallenstein S, Lapinski R, Meier DE (1996) A prospective study of bone loss in African-American and White women-a clinical research center study. J Clin Endocrinol Metab 81:2948–2956PubMedCrossRefGoogle Scholar
  19. 19.
    Sowers M, Randolph JF, Crutchfield M, Jannausch ML, Shapiro B, Zhang B et al (1998) Urinary ovarian and gonadotropin hormone levels in premenopausal women with low bone mass. J Bone Min Res 13(7):1191–1202CrossRefGoogle Scholar
  20. 20.
    Prior JC, Vigna YM, Schechter MT, Burgess AE (1990) Spinal bone loss and ovulatory disturbances. N Engl J Med 323:1221–1227PubMedCrossRefGoogle Scholar
  21. 21.
    Sioban H, Schuman P, Cohen M, Ohmit SE, Cu-Uvin S, Lin X et al (2000) Effect of HIV infection on menstrual cycle length. J Acquir Immune Defic Syndr 24:68–75Google Scholar
  22. 22.
    Money DM, Arikan YY, Remple V, Sherlock C, Craib K, Birch P et al (2003) Genital tract and plasma human immunodeficiency virus viral load throughout the menstrual cycle in women who are infected with ovulatory human immunodeficiency virus. Am J Obstet Gynecol 188(1):122–128PubMedCrossRefGoogle Scholar
  23. 23.
    Clark RA, Mulligan K, Stamenovic E, Chang B, Watts H, Benson C (2001) Frequency of anovulation and early menopause among women enrolled in selected adult aids clinical trials group studies. JID 184:1325–1327PubMedCrossRefGoogle Scholar
  24. 24.
    Swain MC, Bulbrook RD, Hayward JL (1974) Ovulatory failure in a normal population and in patients with breast cancer. J Obstet Gynaecol Br Commonw 81(8):640–643PubMedGoogle Scholar
  25. 25.
    Prior JC, Vigna YM, Barr SI, Rexworthy C, Lentle BC (1994) Cyclic medroxyprogesterone treatment increases bone density: a controlled trial in active women with menstrual cycle disturbances. Am J Med 96:521–530PubMedCrossRefGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2007

Authors and Affiliations

  • J. Prior
    • 1
  • D. Burdge
    • 2
  • E. Maan
    • 3
  • R. Milner
    • 4
  • C. Hankins
    • 5
  • M. Klein
    • 6
  • S. Walmsley
    • 7
  1. 1.Medicine/EndocrinologyUniversity of British ColumbiaVancouverCanada
  2. 2.Medicine/Infectious Disease, BC Women’s Hospital, Oak Tree ClinicUniversity of British ColumbiaVancouverCanada
  3. 3.BC Women’s Hospital, Oak Tree ClinicVancouverCanada
  4. 4.EpidemiologyBC Women’s Hospital, Oak Tree ClinicVancouverCanada
  5. 5.United Nations, UNAIDSNew YorkUnited States
  6. 6.MedicineMcGill University, Montreal Chest InstituteMontrealCanada
  7. 7.MedicineUniversity of Toronto, Toronto General Research InstituteTorontoCanada

Personalised recommendations